Pediatric Infection and Vaccine

  • 제31권1호
  • /
  • Pages.1-11
  • /
  • 2024
  • /
  • 2384-1079(pISSN)
  • /
  • 2384-1087(eISSN)
대한소아감염학회 (The Korean Society of Pediatric Infectious Diseases)
권호 표지
DOI QR코드

DOI QR Code

Trend in Measles Seroprevalence in the Western Pacific Region: A Systematic Review

  • Ji Won Park (Department of Pediatrics, Korea University Anam Hospital) ;
  • Young June Choe (Department of Pediatrics, Korea University Anam Hospital)
  • 투고 : 2023.03.24
  • 심사 : 2024.01.21
  • 발행 : 2024.04.25
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

홍역의 예방을 위한 백신이 도입되었음에도 불구하고, 최근 십수년 간 영유아 및 성인 인구에서 홍역 발생이 지속되고 있다. 본 종설에서는 서태평양지역(Western Pacific Region, WPR)에서 수행되었던 홍역 항체양성도 연구들을 체계적으로 검토하여 홍역에 대한 집단면역도의 추이를 평가하고자 하였다. 서태평양지역에서 수행된 항체양성도 연구에서 도출된 전 연령대의 항체 유병율을 조사한 관찰 연구를 탐색하기 위해 온라인 데이터베이스 PubMed과 Embase를 검색하였다. 다음 변수들이 서로 다른 연구군에서 추출되다: 논문 식별자(제목, 제1 저자, 발행 연도), 포함 및 제외 기준, 연구 장소, 대상 연령, 대상 수, 국가/지역, 인구, 방법 및 혈청양성도(%). 검색 결과, 총 69건의 연구가 포함되었다. 1-6세 연령 그룹 중에서의 항체양성도는 중국이 81-100%로, 한국 86-94%로, 호주 77-91%로 상대적으로 높게 나타났다. 7-18세 청소년에서는 중국과 호주에서의 양성도는 시간이 지나도 상대적으로 일정하게 유지되었지만, 한국에서는 2011년(66%), 2014년(69%), 2014년(50%) 등으로 감소하는 추세가 있었다. 비슷한 하향 추세가 한국 성인 인구 중 19-39세에서 2011년(74%), 2019년(71%), 2019년(64%)에서도 관찰되었다.

Despite improvements in vaccine coverage, a resurgence of measles has been reported, especially in the infant and adult populations in recent years. We conducted a systematic review of seroprevalence studies conducted in the Western Pacific Region (WPR) to provide insights into seropositivity trends in different countries. This systematic review aimed to collect data from all available measles seroprevalence studies to characterize the differences in population immunity against measles in different countries. We searched the online databases PubMed and Embase to identify: 1) observational studies that investigated seroprevalence in all age groups, and 2) results reported as antibody levels. The following variables were extracted from different study arms: paper identification (title, first author, publication year), inclusion and exclusion criteria, study site, age of subjects, number of subjects, country/area, population, methods, and seropositivity (%). The search yielded a total of 69 studies included in the review. Among the 1-6-year-old group, seropositivity remained relatively high, at 81-100% in China, 86-94% in Korea, and 77-91% in Australia. In adolescents aged 7-18-years old, seropositivity was relatively constant in China and Australia over time; however, a decreasing trend was noted in Korea in 2011 (66%), 2014 (69%), and 2014 (50%) in this age group. A similar downward trend was observed among Korean adults aged 19-39 years in 2011 (74%), 2019 (71%), and 2019 (64%). Children are likely to be protected by universal vaccination programs in WPR countries and regions. However, susceptible individuals with waned immunity may be present among the adult population.

키워드

참고문헌

  1. Wang R, Jing W, Liu M, Liu J. Trends of the global, regional, and national incidence of measles, vaccine coverage, and risk factors in 204 countries from 1990 to 2019. Front Med (Lausanne) 2022;8:798031.
  2. Gastanaduy PA, Goodson JL, Panagiotakopoulos L, Rota PA, Orenstein WA, Patel M. Measles in the 21st century: progress toward achieving and sustaining elimination. J Infect Dis 2021;224 Suppl 2:S420-8.
  3. Hagan JE, Kriss JL, Takashima Y, Mariano KM, Pastore R, Grabovac V, et al. Progress toward measles elimination - Western Pacific Region, 2013-2017. MMWR Morb Mortal Wkly Rep 2018;67:491-5.
  4. Cousins S. Measles: a global resurgence. Lancet Infect Dis 2019;19:362-3.
  5. Dimala CA, Kadia BM, Nji MA, Bechem NN. Factors associated with measles resurgence in the United States in the post-elimination era. Sci Rep 2021;11:51.
  6. Leong WY, Wilder-Smith AB. Measles resurgence in Europe: migrants and travellers are not the main drivers. J Epidemiol Glob Health 2019;9:294-9.
  7. Ammari LK, Bell LM, Hodinka RL. Secondary measles vaccine failure in healthcare workers exposed to infected patients. Infect Control Hosp Epidemiol 1993;14:81-6.
  8. Boulton ML, Wang X, Zhang Y, Montgomery JP, Wagner AL, Carlson BF, et al. A population profile of measles susceptibility in Tianjin, China. Vaccine 2016;34:3037-43.
  9. Chong KC, Zhang C, Zee BC, Luo T, Wang L, Tam GC, et al. Interpreting the transmissibility of measles in two different post periods of supplementary immunization activities in Hubei, China. Vaccine 2017;35:1024-9.
  10. Fu C, Xu J, Liu W, Zhang W, Wang M, Nie J, et al. Low measles seropositivity rate among children and young adults: a sero-epidemiological study in southern China in 2008. Vaccine 2010;28:8219-23.
  11. Han K, Chen S, Tang C, Wen J, Li J, Ni J, et al. The epidemiological and serological characteristics of measles in Dongguan, China, 2005-2014. Hum Vaccin Immunother 2016;12:2181-7.
  12. He H, Chen EF, Li Q, Wang Z, Yan R, Fu J, et al. Waning immunity to measles in young adults and booster effects of revaccination in secondary school students. Vaccine 2013;31:533-7.
  13. Liu Y, Lu P, Hu Y, Wang Z, Deng X, Ma F, et al. Cross-sectional surveys of measles antibodies in the Jiangsu Province of China from 2008 to 2010: the effect of high coverage with two doses of measles vaccine among children. PLoS One 2013;8:e66771.
  14. Liu Y, Tao H, Ma F, Lu P, Hu Y, Ding X, et al. Sero-epidemiology of measles in general population in Jiangsu province of China: application of mixture models to interpret the results from a cross-sectional study. Vaccine 2011;29:1000-4.
  15. Ma C, Li F, Zheng X, Zhang H, Duan M, Yang Y, et al. Measles vaccine coverage estimates in an outbreak three years after the nation-wide campaign in China: implications for measles elimination, 2013. BMC Infect Dis 2015;15:23.
  16. Ma YJ, Bo F, Sun ZD, Huang H, Gao SR, An ZJ. Epidemiological investigation of measles in sera of healthy people in Heilongjiang Province, China. Jpn J Infect Dis 2011;64:208-10.
  17. Pei L, Yang Y, Zhao X, Zhang S, Yuan L, Liu Y, et al. Identify the susceptibility profile to measles in the general population: Serological survey of measles antibodies in Shaanxi province, China, in 2016. Vaccine 2017;35:7250-5.
  18. Su X, Carlson BF, Wang X, Li X, Zhang Y, Montgomery JP, et al. Dried blood spots: an evaluation of utility in the field. J Infect Public Health 2018;11:373-6.
  19. Tang L, Zhou Y, Pan Y, Zhu H. Measles epidemics and seroepidemiology of population in Wujin, Changzhou city, Jiangsu province, China 2015. Vaccine 2017;35:2925-9.
  20. Wang X, Ma M, Hui Z, Terry PD, Zhang Y, Su R, et al. Seroprevalence of measles antibodies and predictors for seropositivity among Chinese Children. Int J Environ Res Public Health 2017;14:605.
  21. Wang Z, Yan R, He H, Li Q, Chen G, Yang S, et al. Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination. PLoS One 2014;9:e89361.
  22. Xiong Y, Wang D, Lin W, Tang H, Chen S, Ni J. Age-related changes in serological susceptibility patterns to measles: results from a seroepidemiological study in Dongguan, China. Hum Vaccin Immunother 2014;10:1097-03.
  23. Yu X, Wang S, Guan J, Mahemuti , Purhati , Gou A, et al. Analysis of the cause of increased measles incidence in Xinjiang, China in 2004. Pediatr Infect Dis J 2007;26:513-8.
  24. Zhang DL, Pan JR, Xie SY, Zhou Y, Shen LZ, Xu GZ, et al. A hospital-associated measles outbreak among individuals not targeted for vaccination in eastern China, 2014. Vaccine 2015;33:4100-4.
  25. Zhang X, Shirayama Y, Zhang Y, Ba W, Ikeda N, Mori R, et al. Duration of maternally derived antibody against measles: a seroepidemiological study of infants aged under 8 months in Qinghai, China. Vaccine 2012;30:752-7.
  26. Zhang Z, Chen M, Wang Y, Li J, Li X, Lu L. Seroepidemiology of measles in Beijing, China: a cross-sectional study. Hum Vaccin Immunother 2019;15:2112-6.
  27. Shin L, Choi JR, Huh K, Kim BR, Hyun K, Kang ES, et al. The association between seropositivity and self-reported history of varicella and measles: can we rely on self-reported history? Am J Infect Control 2018;46:S11-2.
  28. Korea Centers for Disease Control and Prevention. National measles seroprevalence report. Cheongju: Korea Centers for Disease Control and Prevention; 2001.
  29. Centers for Disease Control and Prevention (CDC). Elimination of measles--South Korea, 2001-2006. MMWR Morb Mortal Wkly Rep 2007;56:304-7.
  30. Korea Centers for Disease Control and Prevention. Measles, mumps, hepatitis B seroprevalence report. Cheongju: Korea Centers for Disease Control and Prevention; 2007.
  31. Korea Centers for Disease Control and Prevention. Final report of national serological survey for measles. Cheongju: Korea Centers for Disease Control and Prevention; 2008.
  32. Pang SJ, Choi KM. The change of IgG antibody titer to measles, mumps and rubella according to age. Korean J Pediatr Infect Dis. 2011;18:117-23.
  33. Kim YJ, Kang HJ, Kim SJ, Jeong-Gu , Kim NS. Seroprevalence of measles-specific IgG antibodies in Korean children. J Clin Virol 2015;70:S56.
  34. Bae GR, Lim HS, Goh UY, Yang BG, Kim YT, Lee JK. Seroprevalence of measles antibody and its attributable factors in elementary students of routine 2-dose schedule era with vaccination record. J Prev Med Public Health 2005;38:431-6.
  35. Chang HH, Kim SW, Kwon KT, Kim HI, Kim MJ, Ryu SY, et al. Preliminary report of seroprevalence of anti-measles immunoglobulin G among healthcare workers of 6 teaching hospitals of Daegu, Korea in 2019. Infect Chemother 2019;51:54-7.
  36. Cho HK, Lee H, Kim HW, Kim SS, Kang HJ, Kim IT, et al. Seroprevalences of specific IgG antibodies to measles, mumps, and rubella in Korean infants. J Korean Med Sci 2016;31:1957-62.
  37. Jung J, Kim SK, Kwak SH, Hong MJ, Kim SH. Seroprevalence of measles in healthcare workers in South Korea. Infect Chemother 2019;51:58-61.
  38. Kang HJ, Han YW, Kim SJ, Kim YJ, Kim AR, Kim JA, et al. An increasing, potentially measles-susceptible population over time after vaccination in Korea. Vaccine 2017;35:4126-32.
  39. Kim ES, Choe YJ, Cho H, Kim YJ, Yoon HS, Yang JS, et al. Seroprevalence of measles among children affected by national measles elimination program in Korea, 2010. Vaccine 2012;30:3355-9.
  40. Kim SS, Han HW, Go U, Chung HW. Sero-epidemiology of measles and mumps in Korea: impact of the catch-up campaign on measles immunity. Vaccine 2004;23:290-7.
  41. Watanabe T, Tsuchiya M, Suzuki T, Niwa T, Ohta H, Murakami N. Seroprevalence of measles, rubella, mumps, and varicella among health care workers in Japan. Antimicrob Resist Infect Control 2013;2 Suppl 1:P280.
  42. Asari S, Deguchi M, Tahara K, Taniike M, Toyokawa M, Nishi I, et al. Seroprevalence survey of measles, rubella, varicella, and mumps antibodies in health care workers and evaluation of a vaccination program in a tertiary care hospital in Japan. Am J Infect Control 2003;31:157-62.
  43. Hatakeyama S, Moriya K, Itoyama S, Nukui Y, Uchida M, Shintani Y, et al. Prevalence of measles, rubella, mumps, and varicella antibodies among healthcare workers in Japan. Infect Control Hosp Epidemiol 2004;25:591-4.
  44. Kanamori H, Tokuda K, Ikeda S, Endo S, Ishizawa C, Hirai Y, et al. Prevaccination antibody screening and immunization program for healthcare personnel against measles, mumps, rubella, and varicella in a Japanese tertiary care hospital. Tohoku J Exp Med 2014;234:111-6.
  45. Kanda E, Yamaguchi K, Hanaoka M, Matsui H, Sago H, Kubo T. Low titers of measles antibodies in Japanese pregnant women: a single-center study. J Obstet Gynaecol Res 2013;39:500-3.
  46. Katsuyama M, Koike Y, Hirohara T, Kogawa K. Immune status of representative infectious diseases among Japanese female university students. Int J Adolesc Med Health 2018;30:20160038.
  47. Kimura T, Tsunekawa K, Ogiwara T, Tokue Y, Nara M, Inoue T, et al. Seroprevalence of measles- and mumps-specific immunoglobulin G among Japanese healthcare students increased during 2007-2012. Jpn J Infect Dis 2013;66:411-5.
  48. Kumakura S, Shibata H, Onoda K, Nishimura N, Matsuda C, Hirose M. Seroprevalence survey on measles, mumps, rubella and varicella antibodies in healthcare workers in Japan: sex, age, occupational-related differences and vaccine efficacy. Epidemiol Infect 2014;142:12-9.
  49. Nishiura C, Hashimoto H. Screening for measles vaccination in young Japanese non-healthcare workers through self-reported history. J Occup Health 2012;54:154-7.
  50. Shibata H, Kumakura S, Isobe T, Hirose M, Ohe M, Nishimura N, et al. Comparative analysis of a complement fixation assay and enzyme immunoassay to determine the seroprevalence of measles and varicella in a survey of healthcare workers. J Int Med Res 2013;41:224-30.
  51. Shoho Y, Kimura T, Yanagawa Y, Saito A, Inoue T, Suto C, et al. Vaccination status and antibody titers against rubella and measles among Japanese female college students majoring in childcare between 2015 and 2018. Tohoku J Exp Med 2018;246:73-9.
  52. Takemoto K, Nishimura N, Kozawa K, Hibino H, Kawaguchi M, Takeuchi S, et al. Time-series analysis comparing the prevalence of antibodies against nine viral species found in umbilical cord blood in Japan. Jpn J Infect Dis 2016;69:314-8.
  53. Tsuji A, Tanioku Y, Nakayama T. Seroepidemiological study on prevalence of measles antibodies in Urawa City. Keio J Med 1998;47:209-11.
  54. Andrews N, Tischer A, Siedler A, Pebody RG, Barbara C, Cotter S, et al. Towards elimination: measles susceptibility in Australia and 17 European countries. Bull World Health Organ 2008;86:197-204.
  55. Causer J, Mira M, Karr M, Hueston L, Burgess M, Alperstein G, et al. Serological survey of measles and rubella immunity in Sydney preschool children. J Paediatr Child Health 2000;36:418-21.
  56. Ferson MJ, Robertson PW, Donovan JW. Measles immunity and immunization status in under-5-year-old children in New South Wales: a population-based study. J Paediatr Child Health 1998;34:339-41.
  57. Gidding HF, Quinn HE, Hueston L, Dwyer DE, McIntyre PB. Declining measles antibodies in the era of elimination: Australia's experience. Vaccine 2018;36:507-13.
  58. Gidding HF, Wood J, MacIntyre CR, Kelly H, Lambert SB, Gilbert GL, et al. Sustained measles elimination in Australia and priorities for long term maintenance. Vaccine 2007;25:3574-80.
  59. Gilbert GL, Escott RG, Gidding HF, Turnbull FM, Heath TC, McIntyre PB, et al. Impact of the Australian measles control campaign on immunity to measles and rubella. Epidemiol Infect 2001;127:297-303.
  60. Hogg GG, Darlington RJ, Hogg KG, Lester R. Measles immunity and immunisation status in Australian children 1 to 4 years of age. J Paediatr Child Health 2006;42:165-9.
  61. Kelly H, Riddell MA, Gidding HF, Nolan T, Gilbert GL. A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia. Vaccine 2002;20:3130-6.
  62. Kelly HA, Gidding HF, Karapanagiotidis T, Leydon JA, Riddell MA. Residual susceptibility to measles among young adults in Victoria, Australia following a national targeted measles-mumps-rubella vaccination campaign. BMC Public Health 2007;7:99.
  63. Paxton GA, Rice J, Davie G, Carapetis JR, Skull SA. East African immigrant children in Australia have poor immunisation coverage. J Paediatr Child Health 2011;47:888-92.
  64. Riddell MA, Leydon JA, Ugoni A, Kelly HA. A serosurvey evaluation of the school-based measles 'catchup' immunisation campaign in Victorian school-aged children. Aust N Z J Public Health 2001;25:529-33.
  65. Ang LW, Lai FY, Tey SH, Cutter J, James L, Goh KT. Prevalence of antibodies against measles, mumps and rubella in the childhood population in Singapore, 2008-2010. Epidemiol Infect 2013;141:1721-30.
  66. Ho HJ, Low C, Ang LW, Cutter JL, Tay J, Chan KP, et al. Progress towards measles elimination in Singapore. Vaccine 2014;32:6927-33.
  67. Ong G, Hoon HB, Ong A, Chua LT, Kai CS, Tai GK. A 24-year review on the epidemiology and control of measles in Singapore, 1981-2004. Southeast Asian J Trop Med Public Health 2006;37:96-101.
  68. Tan AL, Yoong J, Kasim J, Ciccone G, Sng JG, Tambyah PA. Is measles IgG testing for healthcare providers cost-effective? Results from seroprevalence studies of healthcare providers in a tertiary public hospital with a large foreign-born workforce. Infect Control Hosp Epidemiol 2015;36:1468-71.
  69. Hachiya M, Miyano S, Mori Y, Vynnycky E, Keungsaneth P, Vongphrachanh P, et al. Evaluation of nationwide supplementary immunization in Lao People's Democratic Republic: population-based seroprevalence survey of anti-measles and anti-rubella IgG in children and adults, mathematical modelling and a stability testing of the vaccine. PLoS One 2018;13:e0194931.
  70. Phengxay M, Hayakawa Y, Phan TG, Uneno-Yamamoto K, Tanaka-Taya K, Vongphrachanh P, et al. Seroprevalence of rubella and measles antibodies in Lao PDR. Clin Lab 2011;57:237-44. PUBMED
  71. Weir R, Jennings L, Young S, Brunton C, Murdoch D. National serosurvey of vaccine preventable diseases. Wellington: Ministry of Health; 2009.
  72. Williamson D, Freeman J, Austin P, Allum C, Roberts S. Seroprevalence of measles antibodies among high-risk healthcare workers in Auckland, New Zealand: additional justification for assumption of age-determined immunity based on local data. Infect Control Hosp Epidemiol 2010;31:1082-4.
  73. Mahamud A, Masunu-Faleafaga Y, Walls L, Williams N, Garcia P, Teshale E, et al. Seroprevalence of measles, mumps and rubella among children in American Samoa, 2011, and progress towards West Pacific Region goals of elimination. Vaccine 2013;31:3683-7.
  74. Mao B, Chheng K, Wannemuehler K, Vynnycky E, Buth S, Soeung SC, et al. Immunity to polio, measles and rubella in women of child-bearing age and estimated congenital rubella syndrome incidence, Cambodia, 2012. Epidemiol Infect 2015;143:1858-67.
  75. Chuang SK, Lau YL, Lim WL, Chow CB, Tsang T, Tse LY. Mass measles immunization campaign: experience in the Hong Kong Special Administrative Region of China. Bull World Health Organ 2002;80:585-91.
  76. Stambos V, Chaine JP, Kelly H, Sablan M, Riddell M. Low immunity to measles and rubella among female guest workers, northern Mariana Islands. Emerg Infect Dis 2009;15:1872-4.
  77. LeBaron CW, Beeler J, Sullivan BJ, Forghani B, Bi D, Beck C, et al. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment. Arch Pediatr Adolesc Med 2007;161:294-301.
  78. Bianchi FP, Stefanizzi P, De Nitto S, Larocca AM, Germinario C, Tafuri S. Long-term immunogenicity of measles vaccine: an italian retrospective cohort study. J Infect Dis 2020;221:721-8.
  79. Durrheim DN, Baker MG, Capeding MR, Goh KT, Lee D, Papania M, et al. Accelerating measles elimination in the Western Pacific Region during the calm between the storms. Lancet Reg Health West Pac 2022;23:100495.
  80. Choe YJ, Jee Y, Oh MD, Lee JK. Measles elimination activities in the western pacific region: experience from the Republic of Korea. J Korean Med Sci 2015;30 Suppl 2:S115-21.
  81. Ward BJ, Boulianne N, Ratnam S, Guiot MC, Couillard M, De Serres G. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis 1995;172:1591-5.